학술논문
Pegozafermin Led to Significant Metabolic Benefits, in Addition to Robust Beneficial Effects on the Liver, in an Open-label Cohort of a Phase 1b/2a Study in Subjects with Non-alcoholic Steatohepatitis (NASH)
Document Type
Abstract
Author
Source
In Metabolism May 2023 142 Supplement
Subject
Language
ISSN
0026-0495